Robotic Surgery’s Popularity Pushes Intuitive Surgical Stock Up 65% In Q3
This article was originally published in The Gray Sheet
Executive Summary
Accelerating demand for Intuitive Surgical's da Vinci robotic surgical system procedures is driving the firm's stellar stock price growth, including a 65.7% leap in the third quarter
You may also be interested in...
Hologic Women’s Health Biz Wows Investors As Stock Soars 45% In 2007
Hologic is looking this year to build on its status as the largest company dedicated to women's health care by launching a three-dimensional digital mammography system capable of significantly improved performance over 2D systems
Hologic Women’s Health Biz Wows Investors As Stock Soars 45% In 2007
Hologic is looking this year to build on its status as the largest company dedicated to women's health care by launching a three-dimensional digital mammography system capable of significantly improved performance over 2D systems
Earnings Calls In Brief
Johnson & Johnson/Cordis: Sales of Cypher sirolimus-eluting coronary stents in the United States declined 44% from a year ago to $185 million in the third quarter, the firm reports Oct. 16. Internationally, sales of the device were off 40% to $190 million. The firm blamed reduced percutaneous coronary intervention procedure volumes, a decreased penetration rate for drug-eluting stents versus bare-metal stents, and burgeoning overseas competition. The drug-eluting stent market has declined by over 40% in the United States and over 10% internationally, J&J estimates. The firm believes its share of the U.S. market has been stable at about 46%, while international share of 37% was down from 51% a year ago. Worldwide, Cypher's market share is about 41%, the firm says. Overall, J&J's medical devices and diagnostics segment reported Q3 sales of $5.2 billion, up 6% from a year ago. Company-wide, the diversified drug and medical technology firm generated revenue of $15 billion, up 12.7% from a year ago